Crossref
FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray
JAMA · 2023
DOI: 10.1001/jama.2023.9608 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Narcotic Antagonists, Nasal Sprays. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Narcotic AntagonistsNasal SpraysAnalgesics, OpioidNaltrexoneDrug ApprovalUnited StatesTime Factors
Substanzen
Analgesics, OpioidnalmefeneNaltrexoneNarcotic AntagonistsNasal Sprays
Zitieren
APA
Harris, E. (2023). FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray. JAMA. https://doi.org/10.1001/jama.2023.9608
Vancouver
Harris E. FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray. JAMA. 2023. doi:10.1001/jama.2023.9608
BibTeX
@article{Harris2023,
author = {Harris, Emily},
title = {FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.9608}
}
EUVIMED